MedTrace Logo

Combination Therapy With Fluoroquinolone in Staphylococcus Aureus Bacteremia

NCT00548002 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 430

Last updated 2007-10-23

No results posted yet for this study

Summary

To study whether fluoroquinolone (trovafloxacin or levofloxacin), added to standard treatment, could reduce the high mortality and complication rates in Staphylococcus aureus bacteremia.

Conditions

  • Staphylococcus Aureus
  • Bacteremia
  • Endocarditis
  • Sepsis

Interventions

DRUG

trovafloxacin and levofloxacin

Trovafloxacin: \<60 kg 200 mg iv/orally once daily and \>60 kg 300 mg iv/orally once daily Levofloxacin: \< 60 kg 500 mg iv/orally once daily and \>60 kg 500 mg iv/orally bid

Sponsors & Collaborators

  • University of Helsinki

    lead OTHER

Principal Investigators

  • Eeva Ruotsalainen, MD · Division of Infectious Diseases, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-01-31
Completion
2002-08-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00548002 on ClinicalTrials.gov